Comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 vs 4 Hydroxyphenylacetic Aciduria C1848680
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Fetoplacental Androgens Excess and 4 Hydroxyphenylacetic Aciduria for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
A condition where the placenta and fetus together produce excess androgens, affecting an XX embryo's development. It is present at birth. Multidisciplinary care helps manage physical and hormonal aspects.
4 Hydroxyphenylacetic Aciduria C1848680
A metabolic disorder where the body cannot properly break down certain amino acids. Typically detected in infancy through screening. Treated with dietary modifications and monitoring.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Variable
4 Hydroxyphenylacetic Aciduria C1848680
Variable
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
severe
4 Hydroxyphenylacetic Aciduria C1848680
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Chronic
4 Hydroxyphenylacetic Aciduria C1848680
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
No
4 Hydroxyphenylacetic Aciduria C1848680
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
reproductive
4 Hydroxyphenylacetic Aciduria C1848680
metabolic
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
endocrine
4 Hydroxyphenylacetic Aciduria C1848680
metabolic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-fetoplacental-androgens-excess-C5679876 and 4-hydroxyphenylacetic-aciduria-C1848680 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 4 Hydroxyphenylacetic Aciduria C1848680 | Discriminating power |
|---|---|---|---|
| Genital development | Atypical genital development may be present at birth from excess androgen exposure. | Genital development is not described as the primary feature. | High |
| Metabolic findings | No amino-acid breakdown abnormality is established by the source. | Abnormal handling of certain amino acids, often found in infancy. | High |
| Primary system involved | Reproductive and endocrine development are central. | Metabolic pathways are central. | Moderate |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 when
Newborn with atypical genital development
Source links excess fetoplacental androgens to XX development.
Moderate
Suspected congenital endocrine DSD
Category and body system point to endocrine-reproductive care.
Moderate
Need for multidisciplinary sex-development evaluation
Source states multidisciplinary care addresses physical and hormonal aspects.
High
Choose 4 Hydroxyphenylacetic Aciduria C1848680 when
Infant metabolic screening abnormality
Source says detection is typically through infancy screening.
Moderate
Suspected amino-acid metabolism disorder
Description centers on impaired breakdown of certain amino acids.
Moderate
Dietary monitoring is the stated management focus
Source mentions dietary modification and monitoring, without doses.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 4 Hydroxyphenylacetic Aciduria C1848680 | Interpretation |
|---|---|---|---|
| Clinical genital examination | May show atypical development; exact findings are not specified. | No characteristic genital finding is established. | Supports considering DSD, not a metabolic diagnosis. |
| Newborn metabolic screening or urine organic acids | Not established as diagnostic for this DSD. | May detect the metabolic abnormality; cutoffs are not supplied. | An abnormal result needs clinician confirmation and is not itself a diagnosis. |
| Karyotype or sex-chromosome assessment | Concept specifies 46,XX; testing confirms chromosomal context. | No specific karyotype pattern is established. | Chromosomal results must be interpreted with endocrine findings. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
- Outcome
- Chronic congenital condition; specific outcomes are not established.
- Factors
- Hormonal findings, anatomy, and access to multidisciplinary care.
4 Hydroxyphenylacetic Aciduria C1848680
- Outcome
- Chronic metabolic condition of moderate stated severity; outcomes are not established.
- Factors
- Detection timing, metabolic control, and monitoring; no treatment doses are specified.
Time frame: From birth or infancy into ongoing follow-up; exact course varies.
Individual results, specialist assessment, and response to recommended care.
Complications comparison
| Complication | Presentation |
|---|---|
| Hormonal or developmental effects | Physical and hormonal aspects may require ongoing specialist care. Not described as the main complication. Exact complications and rates are not established. |
| Metabolic imbalance | Not established by the source. May relate to impaired amino-acid breakdown. Severity and laboratory thresholds are not provided. |
| Long-term monitoring needs | Chronic course with multidisciplinary follow-up is suggested. Chronic monitoring and dietary management are suggested. Outcomes cannot be compared quantitatively from these data. |
Patient education highlights
- HighDifferent conditions
One affects sex development through androgen excess; the other concerns amino-acid metabolism.
- HighSpecialist interpretation
Abnormal findings require clinician review and should not be self-diagnosed.
- MediumCare planning
Ask about endocrine, genetic, or metabolic referral and what monitoring is appropriate.